GlassScriptPhysician profile
Digant Nanavati
NPI 1811959935
$26,355.16
in general payments reported to CMS, 2019-2025
83 companies · $4,065 in 2025
The $4,065 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,703 · 2020: $3,009 · 2021: $3,746 · 2022: $4,244 · 2023: $4,445 · 2024: $4,143 · 2025: $4,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $89.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,563.31 |
| Education | $89.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,076.32 | 2019-2025 | Otezla, Repatha, Prolia |
| Pfizer INC. | $1,981.87 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,962.66 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $1,914.23 | 2021-2025 | |
| Novo Nordisk INC | $1,740.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,668.83 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,416.83 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astellas Pharma US INC | $1,074.48 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $997.90 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $882.41 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $877.05 | 2021-2025 | |
| Amarin Pharma, INC. | $801.05 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $654.39 | 2019-2024 | Austedo Xr, Ajovy, Ajovy |
| Janssen Pharmaceuticals, INC | $583.80 | 2019-2022 | |
| Shield Therapeutics INC | $533.04 | 2023-2025 | Accrufer |
Show all 83 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Digant Nanavati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.